Kubryń Natalia, Fijałkowski Łukasz, Nowaczyk Jacek, Jamil Amer, Nowaczyk Alicja
Department of Organic Chemistry, Faculty of Pharmacy, Ludwik Rydygier Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 2 dr. A. Jurasza St., 85-094 Bydgoszcz, Poland.
Department of Physical Chemistry and Physicochemistry of Polymers, Faculty of Chemistry, Nicolaus Copernicus University, 7 Gagarina St., 87-100 Toruń, Poland.
Molecules. 2025 May 11;30(10):2123. doi: 10.3390/molecules30102123.
The publication focuses on the innovative applications of PROTAC (proteolysis-targeting chimera) technology in modern pharmacotherapy, with particular emphasis on cancer treatment. PROTACs represent an advanced therapeutic strategy that enables selective protein degradation, opening new possibilities in drug design. This technology shows potential in the treatment of cancers, viral infections (such as HIV and COVID-19), and chronic diseases including atherosclerosis, Alzheimer's disease, atopic dermatitis, and Huntington's disease. Promising results from clinical studies on the compound ARV-471 confirm the effectiveness of this approach. New types of PROTACs, like TF-PROTAC and PhosphoTAC, are designed to enhance the effectiveness, stability, and absorption of treatment drugs. The conclusions of the review highlight the broad therapeutic potential of PROTACs in various diseases and their relevance for the future of therapies, particularly in oncology.
该出版物聚焦于PROTAC（蛋白酶靶向嵌合体）技术在现代药物治疗中的创新应用，尤其着重于癌症治疗。PROTAC代表了一种先进的治疗策略，能够实现选择性蛋白质降解，为药物设计开辟了新的可能性。这项技术在癌症、病毒感染（如HIV和COVID-19）以及包括动脉粥样硬化、阿尔茨海默病、特应性皮炎和亨廷顿病在内的慢性疾病治疗中显示出潜力。关于化合物ARV-471的临床研究取得的有前景的结果证实了这种方法的有效性。新型PROTAC，如TF-PROTAC和PhosphoTAC，旨在提高治疗药物的有效性、稳定性和吸收性。该综述的结论突出了PROTAC在各种疾病中的广泛治疗潜力及其对未来治疗的相关性，尤其是在肿瘤学领域。
